Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy

  • Wu, Xue-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Lung cancer was one of the most common cancers in both men and women all over the world. In this study, we aimed to clarify who could survive after long term chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods: We enrolled 186 patients with stage IV NSCLC after long term chemotherapy from Jun 2006 to Nov 2014 diagnosed in Jiangsu Cancer Hospital. Multiple variables like age, gender, smoking, histology of adenocarcinoma and squamous-cell cancer, number of metastatic sites, metastatic sites (e.g. lung, brain, bone, liver and pleura), hemoglobin, lymphocyte rate (LYR), Change of LYR during multiple therapies, hypertension, diabetes, chronic bronchitis, treatments (e.g.radiotherapy and targeted therapy) were selected. For consideration of factors influencing survival and response for patients with advanced NSCLC, logistic regression analysis and Cox regression analysis were used in an attempt to develop a screening module for patients with elevated survival after long term chemotherapy become possible. Results: Of the total of 186 patients enrolled, 69 survived less than 1 year (short-term group), 45 one to two years, and 72 longer than 3 years (long-term group). For logistic regression analysis, the short-term group was taken as control group and the long-term group as the case group. We found that age, histology of adenocarcinoma, metastatic site (e.g. lung and liver), treatments (e.g. targeted therapy and radiotherapy), LYR, a decreasing tendency of LYR and chronic bronchitis were individually associated with overall survival by Cox regression analysis. A multivariable Cox regression model showed that metastatic site (e.g. lung and liver), histology of adenocarcinoma, treatments (e.g. targeted therapy and radiotherapy) and chronic bronchitis were associated with overall survival. Thus metastatic site (e.g. lung and liver) and chronic bronchitis may be important risk factors for patients with advanced NSCLC. Gender, metastatic site (e.g. lung and liver), LYR and the decreasing tendency of LYR were significantly associated with long-term survival in the individual-variable logistic regression model (P<0.05). On multivariate logistic regression analysis, gender, metastatic site (e.g. lung and liver) and the decreasing tendency of LYR associated with long-term survival. Conclusions: In conclusion, female patients with stage IV adenocarcinoma of NSCLC who had decreasing tendency of LYR during the course therapy and had accepted multiple therapies e.g. more than third-line chemotherapy, radiotherapy and/or targeted therapy might be expected to live longer.

Keywords

References

  1. Dehing-Oberije C, Aerts H, Yu S, et al (2011). Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys, 81, 360-8. https://doi.org/10.1016/j.ijrobp.2010.06.011
  2. Donovan MJ, Kotsianti A, Bayer-Zubek V, et al (2009). A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib. Eur J Cancer, 45, 1518-26. https://doi.org/10.1016/j.ejca.2009.02.004
  3. Ferketich AK, Niland JC, Mamet R, et al (2013). Smoking status and survival in the national comprehensive cancer network non-small cell lung cancer cohort. Cancer, 119, 847-53. https://doi.org/10.1002/cncr.27824
  4. Gong JP, Yang L, Huang XE, et al (2014). Outcomes based on risk assessment of anastomotic leakage after rectal cancer surgery.Asian Pac J Cancer Prev, 15, 707-12. https://doi.org/10.7314/APJCP.2014.15.2.707
  5. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
  6. Huang XE, Tian GY, one more, et al (2013). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7. https://doi.org/10.7314/APJCP.2013.14.11.6663
  7. Huang XE, Cao J, one more, et al (2014). Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia.Asian Pac J Cancer Prev, 15, 8495-7. https://doi.org/10.7314/APJCP.2014.15.19.8495
  8. Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. https://doi.org/10.7314/APJCP.2014.15.20.8603
  9. Kankesan J, Shepherd FA, Peng Y, et al (2013). Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study. Curr Oncol, 20, 30-7.
  10. Kawaguchi T, Takada M, Kubo A, et al (2010). Performance status and smoking status are independent favorable prognostic factors for survival in nonsmall cell lung cancer: a comprehensive analysis of 26, 957 patients with NSCLC. J Thorac Oncol, 5, 620-30. https://doi.org/10.1097/JTO.0b013e3181d2dcd9
  11. Klein R, Wielage R, Muehlenbein C, et al (2010). Costeffectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol, 5, 1263-72. https://doi.org/10.1097/JTO.0b013e3181e15d16
  12. Kogure Y, Ando M, Saka H, et al (2013). Histology and smoking status predict survival of patients with advanced non-smallcell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. J Thorac Oncol, 8, 753-8. https://doi.org/10.1097/JTO.0b013e31828b51f5
  13. Le Chevalier T, Scagliotti G, Natale R et al (2005). Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-smallcell lung cancer: a meta-analysis of survival outcomes. Lung Cancer, 47, 69-80. https://doi.org/10.1016/j.lungcan.2004.10.014
  14. Lee ES, Son DS, Kim SH, et al (2008). Prediction of recurrencefree survival in postoperative nonsmall cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res, 14, 7397-404. https://doi.org/10.1158/1078-0432.CCR-07-4937
  15. Li C-T, Marek M, Guclu SZ, et al (2011). Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma.J Cancer, 2, 52.
  16. Lu YY, Huang XE, one more, et al (2014)Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.Asian Pac J Cancer Prev, 15, 3335-41. https://doi.org/10.7314/APJCP.2014.15.7.3335
  17. Mok T, Wu YL, Au JS et al (2010). Efficacy and safety of erlotinib in 1242 East/South-east Asian patients with advanced nonsmall cell lung cancer. J Thorac Oncol, 5, 1609-15. https://doi.org/10.1097/JTO.0b013e3181e15d55
  18. Qian YD, Xu X, one more, et al (2014). Clinical safety of chemotherapy for elderly cancer patients complicated with hypertension.Asian Pac J Cancer Prev, 15, 9875-7. https://doi.org/10.7314/APJCP.2014.15.22.9875
  19. Reck M, von Pawel J, Zatloukal P, et al (2009). Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer, AVAil. J Clin Oncol, 27, 1227-34. https://doi.org/10.1200/JCO.2007.14.5466
  20. Reck M, van Zandwijk N, Gridelli C et al (2010). Erlotinib in advanced non-small cell lung cancer efficacy and safety findings of the global phase IV Tarceva lung cancer survival treatment study. J Thorac Oncol, 5, 1616-22. https://doi.org/10.1097/JTO.0b013e3181f1c7b0
  21. Scagliotti G, Hanna N, Fossella F, et al (2009). The differential efficacy of pemetrexed according to NSCLC histology, a review of two Phase III studies. Oncologist, 14, 253-63. https://doi.org/10.1634/theoncologist.2008-0232
  22. Smit EF, van Meerbeeck JP, Lianes P et al (2003). Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced nonsmall- cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol, 21, 3909-17. https://doi.org/10.1200/JCO.2003.03.195
  23. Van der Pijl LL, Birim O, van Gameren M, et al (2010). Validation of a prognostic model to predict survival after non-small-cell lung cancer surgery. Eur J Cardiothorac Surg, 38, 615-9. https://doi.org/10.1016/j.ejcts.2010.03.028
  24. Wu XY, Huang XE, one more, et al (2014). A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Asian Pac J Cancer Prev, 15, 5941-4. https://doi.org/10.7314/APJCP.2014.15.14.5941
  25. Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22. https://doi.org/10.7314/APJCP.2013.14.3.2019
  26. Xiao Y, Liu J, Liu YC, Huang XE, et al (2014). Phase II Study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.Asian Pac J Cancer Prev, 15, 3951-4. https://doi.org/10.7314/APJCP.2014.15.9.3951
  27. Xu C, Huang XE, one more, et al (2014). Drainage alone or combined with anti-tumor therapy for treatment of obstructive jaundice caused by recurrence and metastasis after primary tumor resection. Asian Pac J Cancer Prev, 15, 2681-4. https://doi.org/10.7314/APJCP.2014.15.6.2681
  28. Zhou Q, Shi Y, Chen J, et al (2011). Long-term survival of personalized surgical treatment of locally advanced nonsmall cell lung cancer based on molecular staging. Zhongguo Fei Ai Za Zhi, 14, 86-106 (in Chinese).

Cited by

  1. Diet and Colorectal Cancer Risk in Asia - a Systematic Review vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5389
  2. Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3425
  3. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  4. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485
  5. Silk fibroin peptide suppresses proliferation and induces apoptosis and cell cycle arrest in human lung cancer cells pp.1745-7254, 2018, https://doi.org/10.1038/s41401-018-0048-0